BeiGene In-licenses Janssen Onco-Compounds

BeiGene, Ltd. has entered into exclusive in-licensing and co-development agreements with Janssen Pharmaceutica NV for two clinical-stage oncology compounds. BeiGene will in-license intetumumab (CNTO-95) for clinical development and commercialization in Australia, China, Hong Kong, New Zealand, Korea, Singapore and Taiwan. The two companies will co-develop intetumumab in multiple cancer indications. BeiGene will receive a royalty on global sales outside of these regions. Both parties will share intetumumab development costs. Additionally, BeiGene will in-license MTKi-327 and retain global rights for development and commercialization for an undisclosed upfront payment to Janssen. Janssen is eligible for milestone and royalty payments for MTKi-327.
 
“We are extremely excited to progress these two promising compounds in clinical trials and delighted to be able to initiate a co-development program with intetumumab,” said Peter Ho, M.D., Ph.D., president and co-founder, BeiGene. “Both intetumumab with its encouraging data from Phase II clinical trials and MTKi-327, an inhibitor of several critical cancer signaling pathways, represent promising molecules that have great potential to address the unmet medical needs of oncology patients in China and the Asia-Pacific region.”
 
“We look forward to working with Janssen as a strategic collaborator as we strive to build world-class oncology capabilities in China,” said John Oyler, chief executive officer and co-founder, BeiGene.